Full-Time
Senior Medical Affairs Manager
Multiple Teams
Dexcom
5,001-10,000 employees
Markets real-time CGM devices and analytics
No salary listed
Company Does Not Provide H1B Sponsorship
Remote in USA
Remote
Remote within the United States; must reside in the U.S. No commuting distance requirement; occasional travel up to 25%.
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Dexcom
See people who can refer or advise you
- Typically requires a Bachelor’s degree and a minimum of 13+ years of related experience.
- At this level a graduate degree may be expected with 6 years of related experience.
- You lead value, evidence, and outcomes initiatives that support Dexcom’s evidence-based strategy across products, populations, care settings, and healthcare decision-making environments.
- You develop scientifically rigorous medical resources that translate clinical, real-world, health economic, quality, and outcomes evidence into clear, balanced communications for internal and external stakeholders.
- You serve as a trusted scientific advisor across Medical Affairs, HEOR, Clinical Affairs, External Studies, Data Science, Market Access, Government Affairs, Commercial, Marketing, Clinical Education, and other cross-functional teams to align evidence strategies with enterprise priorities.
- You identify strategic evidence gaps and recommend evidence-generation priorities that address evolving stakeholder needs, healthcare quality initiatives, business objectives, and emerging evidence requirements.
- You establish and maintain scientific relationships with healthcare organizations, health plans, health systems, professional societies, advocacy organizations, quality leaders, and other external stakeholders to advance scientific exchange and evidence-based collaboration.
- You provide expert scientific guidance on evidence assessments, healthcare quality initiatives, value-based care strategies, policy discussions, access-related priorities, and scientific engagement, as appropriate.
- You develop innovative approaches to scientific communication, stakeholder engagement, and evidence translation that strengthen Medical Affairs strategy and support enterprise decision-making.
- You contribute to scientific publications, congress activities, medical education resources, evidence summaries, advisory boards, research collaborations, and scientific exchange initiatives while ensuring all work meets the highest standards of scientific integrity, compliance, and quality.
- You hold an MD, DO, PhD, PharmD, PA, NP, MSN, MPH, MS, or other relevant clinical or scientific degree.
- You are recognized for your scientific expertise and bring significant experience in Medical Affairs, HEOR, healthcare quality, population health, evidence strategy, market access, medical communications, or a related healthcare discipline.
- You demonstrate expert knowledge of clinical research methodology, study design, real-world evidence, health economics, outcomes research, and healthcare quality, with the ability to translate complex evidence into clear, balanced scientific communications.
- You exercise sound scientific judgment and work independently to solve complex, ambiguous challenges where strategic thinking, evaluation of multiple factors, and evidence-based decision-making are essential.
- You influence cross-functional teams and external stakeholders without formal authority, building trusted partnerships and providing scientific leadership across a complex matrix organization.
- You proactively identify emerging healthcare trends, anticipate evolving evidence needs, and recommend innovative approaches that strengthen Medical Affairs strategy and enterprise decision-making.
- You have demonstrated success developing scientific publications, congress presentations, evidence summaries, medical education resources, or other evidence-based scientific communications.
- You bring experience in biotechnology, pharmaceuticals, medical devices, diagnostics, digital health, healthcare technology, or a related industry. Experience in diabetes, cardiometabolic health, continuous glucose monitoring, healthcare quality, population health, value-based care, evidence assessment, payer decision-making, health policy, or external research collaborations is strongly preferred.
- You demonstrate exceptional execution discipline, accountability, adaptability, and attention to quality while managing multiple strategic priorities in a fast-paced environment.
- You are committed to maintaining the highest standards of scientific rigor, ethics, compliance, and integrity in all aspects of Medical Affairs.
Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
Get referred to Dexcom
See people who can refer or advise you
Simplify's Take
What believers are saying
- International revenue grew 26% in Q1 2026, driven by 17% organic global growth [5].
- Free cash flow margin reached 29.7% with operating margin at 21.4%, showing strong leverage [4].
- Acquiring Nutrisense integrates CGM data with personalized nutrition coaching for non-insulin Type 2 users [7].
What critics are saying
- FDA Class I recall of G6/G7 receivers and G7 apps due to missing alerts caused 56 injuries [Negative trends].
- Medicare competitive bidding starting 2027 will cut CGM payments effective 2028, compressing net pricing [Negative trends].
- Activist investor Elliott forced board changes, increasing governance instability and strategic misstep risk [Negative trends].
What makes Dexcom unique
- G7 15 Day delivers 15.5-day wear, the longest CGM authorized by Health Canada [1].
- Stelo is the first FDA-cleared over-the-counter biosensor for children aged 2+ not using insulin [3].
- Dexcom owns a recurring installed base with G6 users migrating to G7 by end-2026 [5].
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%SEB Asset Management AB purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 377,064 shares of the medical device company’s stock, valued at approximately $23,680,000. A number of other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a […]
Dexcom wins 2026 North American Finance Transformation Award for its basware-powered AP automation journey. Date. At the SSON (Shared Services & Outsourcing Network) conference's black-tie gala this year, Dexcom was named winner of the 2026 North American Finance Transformation Award, beating out nominees that included Johnson & Johnson, Siemens, and Genpact. The win recognized Dexcom's AP automation journey, built on Basware and implemented with Extropy Advisors. Extropy CEO Ravit Gutman was in the room. On the latest episode of ExtropyOnAIR, she and host Mike Jasper broke down what made the win stand out, and what else she saw at SSON that's worth paying attention to. Why the Dexcom win matters. The award wasn't handed out for the biggest cost-cutting story on the floor. As Ravit put it: "It wasn't a transformation story that talked about just on metrics and cost savings and all of these different things. It really hit the core of really how it impacted people." The result that stood out: Dexcom didn't outsource its way to efficiency. It automated its AP process and grew invoice volume without adding headcount, and without the overtime that used to come with it. "They have transformed their organization to be able to grow and get and process much more with the same amount of people that they had in the beginning, not requiring to hire anyone and still not have that overtime." Ravit also pointed out that the project was led entirely by two women, Kathy Tanner and Kaitlynn Williams, on the client side, one of the details she was proudest of. Their team's own headline result: eliminating overtime altogether, and getting time back for their employees' households as a direct result of the transformation. For Ravit, the win was also a personal marker: "Starting as a boutique consulting agency, being next to Genpact, Deloitte nominees... and seeing this transformation story, the journey, and our client win that award was an affirmation for me that everything that we do here, all the work, the people-focused transformation, that that is the work that matters." The bigger pattern Ravit is watching: outsourcing vs. transforming. Ravit connected the Dexcom story to something she heard repeatedly across the conference: a disconnect between companies that want to outsource their finance operations and companies that actually want to transform them. "That disconnect that exists between wanting to outsource and wanting to transform, that is a broken model... many of these companies, large organizations, have just outsourced the problem away and they've put their entire purchase-to-pay or order-to-cash practices to a different outsourcing team. The people inside our organization want to implement the change, but you have another side that has no interest essentially in being part of the change." That's the choice Dexcom made differently: transforming the process with the team already in place, rather than routing the problem to an outsourcer. What SSON 2026 revealed about the AI rush in finance. Beyond the award, Ravit's biggest takeaway from SSON was how fast, and how uniformly, the conversation has shifted to AI. "There wasn't a single booth over there on the floor that didn't talk about AI... but that's what sets, once again, that huge gap that exists to the human side of AI, and really understanding how the gap between where all these different solutions are, or where they're trying to take the market to, and how far the people actually understand and are visualizing or planning to get to that stage." Her read: plenty of mature, sophisticated companies at the conference know they need to do something with AI, but very few have a clear answer for where to start. "It became very daunting to many people to understand: okay, I understand where we need to go, but the distance of how do I... what do I take from here from this conference? How does my Monday morning look like? What do I tell my team?" That gap, between the technology on offer and an organization's actual readiness to use it, is exactly the space Extropy positions itself in: leading with purpose and process before technology, not after. "Let's start with a purpose. Let's understand what you're trying to accomplish. How are you defining success? Let's work backwards into the process, the people, and the technology." - Mike Jasper International Women's Day at SSON. The conference also devoted a full day to Women's Day programming, which Ravit said was a highlight for her personally as a woman-owned business founder. "For a man, when they see a job that they want to apply to, if a man sees that he qualifies 60% of it, he will go for it... but for a woman to apply to that job, she needs to make sure that she covers 100% of the job requirements. And even then, she would still try to convince herself why she's not fit." Her takeaway wasn't just about hiring, it was about normalizing what a working leader's life actually looks like: "I'm trying to figure out what does it mean for me to be a female leader, a women-owned company. How do I support the women in my business in the best possible way?" The takeaway. Between the Dexcom win and the AI conversations dominating the floor, the through-line Ravit kept coming back to was the same one Extropy leads with in every engagement: technology alone doesn't transform anything. The organizations getting real results, like Dexcom, are the ones solving for people and process first, and using automation to scale what already works, rather than outsourcing the problem or hoping a new tool closes the gap on its own. Listen to the full conversation on ExtropyOnAIR. Book a Discovery Call to talk through what a Basware-powered AP transformation could look like for your organization.
Helose integrates Oura, WHOOP, and Dexcom. Helose today announced integrations with Oura, WHOOP, and Dexcom - wearable and CGM data now flows into the pre-visit brief for outpatient clinics running between-visit care on Helose. Jun 24, 2026 June 24, 2026 - Helose today announced integrations with Oura, WHOOP, and Dexcom, bringing the wearable and CGM platforms patients already use into the pre-visit brief outpatient clinics open before each visit. Until now, sleep scores, recovery trends, and glucose variability lived in separate apps - useful for patients, invisible to the care team between visits. With these integrations, that data surfaces on the same Helose timeline as chart context, lab results, and practice-number SMS threads. What clinics get. Each integration feeds trends into the patient portfolio - not a second dashboard staff have to check: * Oura - sleep, readiness, HRV, and resting heart rate * WHOOP - recovery, strain, and sleep performance * Dexcom - CGM time-in-range and variability for protocols that track glucose between visits Patients connect through a one-time secure link in their existing text thread with the clinic. No app download, no new login to remember. Who this is for. The integrations are available to Helose pilots in functional and integrative medicine, GLP-1 weight-loss programs, and rural outpatient practices - segments where between-visit wearable context already shapes care plans but rarely reaches the physician before the door opens. Helose does not interpret wearable data or generate clinical recommendations. It dates trends to check-in texts and visit cadence so staff see what changed since the last visit. Availability. Integrations are rolling out to active Helose clinic panels now. Practices on a two-week trial can request wearable connect during onboarding. Helose cite public sources in the text where it matters. For operations and finance context only, not clinical, legal, or investment advice.
Dexcom - project completion. Date: March 30, 2026 John Paul Construction Limited is pleased to mark the completion of the Dexcom Medical Devices Facility, a state of the art manufacturing and office development delivered over a 25-month programme. The facility includes a highly technical production environment with cleanrooms, supporting laboratory and engineering spaces, alongside a four-storey office building. As Dexcom's first manufacturing facility outside of the United States, the project represents a significant milestone for the company's global expansion. Once operational, it will develop and manufacture real time continuous glucose monitoring systems, supporting diabetes management, and improving patient outcomes globally. This project was particularly important to its team, reflecting its capability in delivering complex, high specification life sciences facilities, with a strong focus on quality, safety, and programme certainty. From a sustainability perspective, the project excavated and successfully retained 170,000m^3 of subsoil and topsoil, planted 600 native Irish Oak trees as part of the Athenry Tidy Towns initiative, and is submitting for LEED Gold certification. A strong local supply chain was also central to the success of the project, supporting both delivery and the wider regional economy. Dexcom has been a valued client throughout, and John Paul Construction Limited appreciate the trust placed in John Paul Construction Limited to deliver this significant investment. John Paul Construction Limited would like to thank the design team, its project partners and the wider site team for their commitment and professionalism in bringing this project to completion.
Dexcom Malaysia wins at Healthcare Asia Medtech Awards 2026 for automation. Automation enhances manufacturing efficiency and employee safety across Dexcom Malaysia's operations. Dexcom Malaysia won the Automation Initiative Award - Malaysia in the Healthcare Asia Medtech Awards 2026. The Automated Material Handler System features an Autonomous Mobile Robot (AMR) alongside vertical lifters and conveyors, creating a fully automated route for moving palletised products across a 550-meter span from production areas to the warehouse. By removing the need for employees to manually transport heavy loads, the system significantly reduces physical strain and enhances overall safety on the production floor. Dexcom Malaysia followed a phased approach for rollout. The team started with small-scale pilot runs to test and refine the system. They then scaled it up across operations. The strategy targeted key areas to lower costs, raise efficiency, and improve ergonomics. The AMR itself is engineered to carry loads of up to 650 kg and is equipped with an array of sensors and vision-based navigation technologies. These capabilities enable the robot to move autonomously, avoid collisions, and operate safely alongside people. The system also includes a pallet lifter that automatically raises and lowers pallets for pick-up and drop-off, eliminating risky manual handling steps during palletising. Join Healthcare Asia Magazine community A staging conveyor holds up to 26 pallets across dual lanes, functioning as an intermediate buffer before the next processing stage. By automating these repetitive and time-intensive tasks, employees are freed to focus on higher-value activities. Production floors gain space as finished goods pallets move straight out after palletising. This creates a cleaner, more spacious, and more efficient operating environment. The system's modular architecture means it can easily scale as production grows - new routes, stations, or tasks can be added through simple reprogramming rather than major infrastructure changes. The AMRs use safety-rated sensors to ensure controlled, collision-free movement, whilst automation removes many of the ergonomic risks previously associated with manual pallet transfers. The continuous, uninterrupted operation of the system also reduces idle time and smooths overall workflow, contributing to higher throughput and more consistent production performance. The Healthcare Asia Medtech Awards honours the most exemplary medtech companies across Asia. It serves as a platform for organisations to showcase their pioneering medical devices, life-saving software, or top-notch healthcare solutions, amongst other innovations. The Healthcare Asia Medtech Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's initiatives and contribution to enhancing the industry's overall performance, please contact Julie Anne Nuñez-Difuntorum at [email protected].